I shall confine my discussion of the endocrinology of trophoblastic tumours largely to those aspects which concern screening, diagnosis and the monitoring of therapy and follow up.
The endocrine repertoire of the trophoblast is well known to change sequentially during the course of pregnancy. In general, the endocrinological behaviour of choriocarcinoma resembles that of early pregnancy trophoblast rather than that of late pregnancy. Thus, synthesis of human chorionic gonadotrophin has been detectable in urine or plasma from all 500 cases with active malignant trophoblastic tumour studied at Charing Cross Hospital. On the contrary, human placental lactogen production, which is characteristically present in high concentration in the last trimester of pregnancy, was at a relatively low level and sometimes undetectable even before treatment was started (figure). Similarly, we have observed that the placental isoenzyme of alkaline phosphatase was not increased in the 35 patients we studied (16 gestational choriocarcinoma, seven testicular choriocarcinoma, three ovarian choriocarcinoma, nine invasive mole) (Jacoby, 1972; Jacoby and Bagshawe, 1972) . oa-Fetoprotein (oFP) has been in the normal range in most patients with gestational choriocarcinoma and invasive mole, but elevated values were found in patients with hepatic metastases. oxFP values are also low in hydatidform mole unless there is an associated fetus (Seppala et al, 1972; Ishiguro, 1975) .
Another pregnancy associated ,8i glycoprotein variously identified as 'SP1' (Bohn, 1974) or Papp-C (Lin et al, 1974) has been identified in the serum of patients with trophoblastic tumours (Tatarinov et al, 1974) . Urinary oestrogen excretion rates in women with mole were found to be generally above normal values in non-pregnant women but to be lower than those of women at a corresponding stage of normal pregnancy and they varied widely (Brinck-Johnsen et al, 1970) . These workers found, and this is also our experience, that in patients with choriocarcinoma, oestrogen production was in the normal range for the non-pregnant or only marginally elevated. Serum progesterone values were elevated in most patients with metastatic disease and, with extensive disease, reached those obtained during pregnancy (Dawood, 1975) . As an index of tumour activity it was, however, thought inferior to hCG, even when this was measured by a haemagglutination method. Plasma testosterone has been reported to be elevated, particularly in patients whose ovaries were enlarged (Samaan et al, 1972) . The testosterone content of ovarian cyst fluid suggested that its major source was the ovary and a later study has shown that androstenedione and dihydrotesterone are increased in similar cases (Samaan et al, 1973) .
In our experience with approximately 500 cases of invasive mole and choriocarcinoma, overt hyperthyroidism has been present in about 1 %. It is, however, relatively common in patients with hydatidiform mole (Kock et al, 1966) . Increased thyroid function without clinical hyperthyroidism may also be observed (Odell et al, 1963) . Evidence that human chorionic thyrotropin (HCT) is distinct from pituitary thyroid stimulating hormone (TSH) and that the thyroid stimulator in hydatidiform mole is a distinct entity, at least immunologically, has been presented (Hershman et al, 1970) . More recently the same group have presented evidence suggesting that the thyrotropin of hydatidiform mole is hCG (Kenimer et al, 1975) . Measurements of hCG in urine, plasma and CSF provide a valuable 'marker' for these tumours. One important application is the screening of cases for treatment after hydatidiform mole. This is probably the first biochemical screening for cancer to come into clinical use and it is used to avoid treating unnecessarily those patients whose invasive moles undergo spontaneous degeneration, whilst ensuring that patients requiring treatment are identified at a stage and time when their tumours can be treated successfully (Bagshawe et al, , 1973 (Stone et al, 1976) .
It may take up to six months for gonadotrophin values to return to normal after hydatidiform mole and when this is achieved spontaneously it is generally a good prognostic sign. However, we have now seen four patients out of approximately 1200 followed up who have developed choriocarcinomas without new conceptions being evident; hCG/LH values had been normal for two to 12 months. There is also a small group of patients who, having had a mole and subsequently one or more pregnancies, then developed choriocarcinoma. Details of these observations will be published elsewhere.
The isolation of the distinctive fi subunit of hCG has resulted in the development and automation of a radioimmunoassay (Kardana and Bagshawe, 1976) which discriminates between hCG and LH and which as a result of this improved specificity, is 10 to 100 times more sensitive. At present, assay of f-hCG is performed only on plasma and it is especially 141 valuable in monitoring therapy and in following up treated cases. However, for following up patients after hydatidiform mole the convenience of urinary assays remains important.
The identification of hCG in the body fluids of patients who have not had a hydatidform mole evacuated in the previous six months has, in my experience, always been indicative of cancer. With the use of sensitive f-hCG assays hCG production by non-trophoblastic tumours has been identified more frequently (Braunstein et al, 1973) . Thus, hCG production by the non-pregnant subject should be assumed to be associated with a trophoblastic tumour until proven otherwise.
Since occult choriocarcinoma may cause cerebral haemorrhage, gastrointestinal bleeding, pulmonary hypertension, pleuritic pain, hepatomegaly and haematuria (Magrath et al, 1971) , greater use of fhCG assays in these conditions could avoid unnecessary and sometimes undesirable surgery.
Observations on a large number of patients in our series (Bagshawe, 1969) Bagshawe et al, 1968; Bagshawe and Harland, 1976) and regular determinations can be used for presymptomatic detection and monitoring.
The introduction ofmethotrexate for the treatment of trophoblastic tumours (Li et al, 1956 ) was one of the decisive events in the development of anti-cancer chemotherapy. Since then it has become clear that this agent used alone is capable of eradicating totally some of these potentially fatal tumours. But it is important to recognize that whilst it rarely fails to eradicate invasive moles when used as a single agent, in choriocarcinoma it produces a therapeutic response in about 70 % and is curative in only about 25 % of cases. Some methotrexate-resistant patients were found to respond to actinomycin D (Ross et al, 1962) but combination chemotherapy was introduced early in an attempt to avoid drug resistance (Bagshawe and McDonald, 1960) .
Ideally it should be possible to compare different regimens of chemotherapy from published accounts of patients treated. Unfortunately, this is not so. One of the principal difficulties in assessing progress in the treatment of these tumours has been the concept of 'malignant trophoblastic disease'. The term was introduced to overcome the fact that in certain patients treated by chemotherapy there was no histological diagnosis and, therefore, it was not known whether the patients had invasive moles or choriocarcinoma. Combined with evidence that 'early' treatment is better than 'late', and given the arbitrariness of the indications for chemotherapy after hydatidiform mole, the inexactitude of the concept precludes comparison of treatments, since it admits to the treated series patients with unproven mole and choriocarcinoma.
The treatment of 8% of patients with mole by chemotherapy is considered appropriate in the UK, and in N America about 20 % are treated. Data from the prechemotherapy era indicated that about 2 to 3 % of moles gave rise to choriocarcinoma and a further 2 to 3 % to life-threatening invasive moles, so it has to be recognized that many patients are being treated either unnecessarily, or to preserve reproductive function rather than life.
Chemotherapy has come to be used for a highly heterogeneous group of patients. For many years our approach was to initiate it with a non-toxic methotrexate-folinic acid regimen and, then, if the response were inadequate, actinomycin D and, later, other drugs were used. This method has some advantages, but it now appears better to tailor treatment according to the risk both of disease and of treatment to the individual patient. At the same time another principle has emerged, though as yet it is less clearly defined: resistance to one drug, once it has become established, appears to reduce the response to other drugs. For this reason, sequential therapy starting with the less effective and less toxic forms of treatment and progressing towards multidrug therapy has given way to the policy of defining the likelihood of drug resistance at the start of treatment.
In In the series to date, more than 100 women have had one or more normal pregnancies subsequently to treatment. Clinical and historical examination of 36 patients available for study has not revealed any residual abnormalities of hepatic or haemopoietic function. One patient has hypertension following methotrexate-associated renal failure. Their obstetric histories following chemotherapy were worse than those of a comparable control group but they were not worse than their own obstetric histories before chemotherapy (Walden and Bagshawe, 1976) . The only second malignancy so far reported in the surviving patients, approximately 400 in all, is one cervical carcinoma in situ detected on routine cytology.
